Introduction {#s1}
============

Articular cartilage covering the surface of joints plays a very important role in bearing loads, absorbing mechanical shocks, and enabling synovial joints to articulate with low friction ([@B12]). Acute trauma, repetitive joint use, and degenerative joint disease may lead to cartilage and osteochondral injuries ([@B65]; [@B22]). Articular cartilage has a very limited regenerative and self-healing potential due to its avascular, aneural, and alymphatic characteristics and a low number of progenitor cells ([@B60]). Many attempts have been made to identify the ideal treatment for cartilage lesions, including bone marrow stimulation (BMS) techniques ([@B35]), osteochondral autografts and allografts ([@B47]), and cell-based cartilage repair procedures, including autologous chondrocyte implantation (ACI) ([@B61]), mesenchymal stem cell (MSC)-based therapy ([@B22]; [@B44]) and tissue-engineered cartilaginous grafts ([@B85]; [@B18]; [@B80]; [@B84]). Since BMS techniques, osteochondral transplantation, and ACI have limitations and shortcomings, such as fibrocartilage regeneration, donor site complications, graft failure, dedifferentiation of seed cells, and two-stage invasive surgical procedures ([@B20]; [@B1]; [@B61]), MSCs, which are multipotent progenitor cells with an intrinsic potential for multilineage differentiation, self-renewal, low immunogenicity, anti-inflammatory activity, and immunomodulatory effects by suppressing the graft-versus-host reaction, may be obtained from multiple tissues of individual patients, and these cells are easily cultured, amplified, and purified ([@B24]; [@B25]). MSCs are widely used in cartilage repair and regeneration as seed cells without concerns regarding increasing the risk of cancer ([@B29]; [@B45]; [@B28]). An increasing number of studies have suggested that peripheral blood (PB) is a potential alternative source of MSCs, which have shown similar chondrogenic differentiation potential with bone marrow-derived MSCs (BM-MSCs) in both *in vitro* and *in vivo* studies ([@B22]; [@B78]). PB-derived stem cells (PBSCs) can be obtained by a minimally invasive procedure with fewer complications than bone marrow (BM) harvesting, which has been reportedly associated with haemorrhage, chronic pain, neurovascular injury, and even death ([@B2]). Moreover, PBSCs also have the ability to be used in autologous transplantation, which greatly benefits patients in clinical applications and facilitates the development of a one-stage surgical solution and other cell-based therapies ([@B71]; [@B30]; [@B67]).

Although increasing evidence has shown that PBSCs are a potential alternative source of chondrogenic progenitor cells for cartilage repair, reviews describing the application of PBSCs for cartilage repair and regeneration *in vivo* are lacked. The purpose of this review was to evaluate the treatment efficacy and safety of using PBSCs for cartilage regeneration *in vivo* and attempt to clarify treatment details about cell types, isolation methods, optimal dosages, and implantation methods.

Method {#s2}
======

This review was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and a PRISMA checklist using PubMed, EMBASE, and Web of Science to search for relevant studies published from 1 January 1990 to 31 December 2019 ([@B11]). The search terms used in the selection were "(peripheral OR blood OR circulating OR circulation) AND (mesenchymal OR stem cell OR stromal cell OR progenitor cell OR mononuclear cell OR primitive cell) AND (cartilage OR chondrogenesis OR chondral OR osteochondral OR osteoarthritis) AND (vivo OR human OR patient OR animal OR mouse OR rat OR rabbit OR dog OR sheep OR pig OR horse OR ovine)".

YRC, XY, and FZY independently screened study titles and abstracts from the beginning. Only original research studies published in full English that used PB as the source of chondrogenic progenitor cells for cartilage repair were included in the analysis. Both print journals and e-published journals were eligible for inclusion and screening. However, all non-English language studies, review articles, letters, editorials, conference, patents, and meeting abstracts and studies not involving cartilage regeneration were excluded. Duplicates were excluded. In addition, studies of primary cells that were not derived from the PB and studies that were not related to *in vivo* animal or human experiments or only used non-PB sources were excluded. Disagreements between the authors were resolved by discussion and consensus.

To avoid the omission of relevant studies, we investigated all reference lists of the eligible studies for studies that were likely not identified by the initial retrieval criteria. Unpublished studies were not included in this review. A flowchart of the literature search is shown in [**Figure 1**](#f1){ref-type="fig"}. We reviewed human studies first, and then reviewed the animal studies according to the order of the publication date. Preoperative characteristics of patients and animals, treatment details, and the treatment efficacy and safety of PBSCs were assessed.

![A flowchart of the literature search.](fphar-11-00404-g001){#f1}

Results {#s3}
=======

Description of the Included Studies {#s3_1}
-----------------------------------

Overall, 1,898 publications were retrieved from the initial search. A total of 1,685 potential studies were retained for further identification after 84 non-English language studies and 129 review articles, letters, editorials, conference, and meeting abstracts were excluded. Furthermore, 1,619 duplicates and studies of unrelated topics based on the title and abstract, and 49 basic studies that did not conduct experiments *in vivo* were excluded. We identified 17 *in vivo* studies consisting of 7 human trials and 10 animal studies published between 1990 and 2019 using this retrieval strategy. All reference lists of the 17 included studies were investigated, and an additional human trial ([@B34]) was identified and included in this review. Finally, data from the 18 studies \[8 human studies ([@B34]; [@B65]; [@B70]; [@B66]; [@B69]; [@B76]; [@B22]; [@B67]) and 10 animal studies ([@B71]; [@B6]; [@B7]; [@B22]; [@B17]; [@B31]; [@B85]; [@B16]; [@B8]; [@B9]) published by investigators from seven countries or regions\] were analyzed.

Among the 18 studies, 7 were case reports \[6 in humans ([@B34]; [@B65]; [@B70]; [@B76]; [@B22]; [@B67]) and 1 in horses ([@B71])\], 1 was a human comparative study ([@B69]), 1 was a human randomized controlled trial (RCT) ([@B66]), 1 was a preliminary study (in horses) ([@B6]), 1 was a pilot study (in horses) ([@B7]), 4 involved animal models \[rabbits ([@B23]), sheep ([@B31]), rats ([@B17]), and pigs ([@B85]), 1 was a prospective placebo-controlled study (in dog) ([@B16]), and 2 were randomized, double-blinded, placebo-controlled proof-of-concept study (in horses) ([@B8]; [@B9]) ([**Table 1**](#T1){ref-type="table"}).

###### 

Preoperative characteristics of patients and animals.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                       Study ID   Species (no. of subjects)       Study design                                                              The age/weight of patients or animals   Clinical or imaging examination                                                                                       Types of defects or diseases           Location of lesions                                                      The defect size/ICRS grade
  -------------------- ---------- ------------------------------- ------------------------------------------------------------------------- --------------------------------------- --------------------------------------------------------------------------------------------------------------------- -------------------------------------- ------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------
  **Human studies**    ([@B34])   Human (9)                       Case report                                                               N/A                                     N/A                                                                                                                   Osteochondral defects                  Talus                                                                    0.5×0.7 cm with 0.5-1.0 cm depth\
                                                                                                                                                                                                                                                                                                                                                                                                                          ICRS IV

                       ([@B70])   Human (52)                      Case report                                                               16-55 years old                         N/A                                                                                                                   Cartilage lesions                      Patella (22), medial femoral condyle (38), lateral femoral condyle (6)   4 to 12 cm^2^ (mean 6.2 cm^2^), ICRS grade III and IV

                       ([@B69])   Human (46)                      Comparative study                                                         7-52 years old\                         N/A                                                                                                                   Osteochondral lesions                  Medial femoral condyle                                                   \>4 cm^2^, \> 6 mm deep, ICRS grade IV
                                                                                                                                            (average age: 26 years)                                                                                                                                                                                                                                                       

                       ([@B76])   Human (5)                       Case report                                                               52-59 years old\                        Varus deformity (1.20 ± 0.84°);\                                                                                      Early-stage OA                         Medial condyle (4), patellofemoral (1)                                   ICRS grade III and IV
                                                                                                                                            (median age: 56 years)                  Kellegan Lawrence stages 1-3                                                                                                                                                                                                          

                       ([@B65])   Human (5)                       Case report                                                               19-52 years old                         N/A                                                                                                                   Chondral defects                       Knee                                                                     ICRS grade III and IV

                       ([@B66])   Human (50)                      RCT                                                                       22-50 years old                         N/A                                                                                                                   Chondral defects                       Knee                                                                     ICRS grade III and IV

                       ([@B67])   Human (8)                       Case report                                                               50-56 years old                         Varus deformity                                                                                                       End-stage OA\                          Medial compartment of the knee joint                                     ICRS grade IV
                                                                                                                                                                                                                                                                                                          (bone-on-bone lesions)                                                                                          

                       ([@B22])   Human (1)                       Case report                                                               19 years old                            N/A                                                                                                                   Full-thickness cartilage defects       Lateral femoral trochlea                                                 4 cm^2^\
                                                                                                                                                                                                                                                                                                                                                                                                                          ICRS grade IV

  **Animal studies**   ([@B71])   Horse (1)                       Case report                                                               5 years old                             Severe unilateral forelimb lameness;\                                                                                 Degenerative joint disease             Pastern joint                                                            N/A
                                                                                                                                                                                    new periarticular bone formation                                                                                                                                                                                                      

                       ([@B6])    Horse (50)                      Preliminary study                                                         N/A                                     Mild to moderate clinical lameness;\                                                                                  Degenerative joint disease             Fetlock joint                                                            N/A
                                                                                                                                                                                    positive flexion test                                                                                                                                                                                                                 

                       ([@B7])    Horse (165)                     Pilot study                                                               N/A                                     Clinical lameness; locomotory disorder;\                                                                              Degenerative joint disease             Stifle joint (30),\                                                      N/A
                                                                                                                                                                                    positive flexion test                                                                                                                                        fetlock joint (58),\                                                     
                                                                                                                                                                                                                                                                                                                                                 coffin joint (43),\                                                      
                                                                                                                                                                                                                                                                                                                                                 pastern joint (34)                                                       

                       ([@B23])   New Zealand white rabbit (30)   Animal models                                                             4 months old                            N/A                                                                                                                   Full-thickness osteochondral defects   Trochlear groove of the distal femur                                     5 mm in diameter and 1-2 mm in depth

                       ([@B31])   Mountain sheep (24)             Animal models                                                             3-5 years old                           N/A                                                                                                                   Full-thickness osteochondral defects   Medial femoral condyle (MFC)                                             6.0 mm in diameter and 8 mm in depth

                       ([@B17])   SD rat (28)                     Animal models                                                             12 weeks old                            N/A                                                                                                                   Papain-induced OA model                Knee joints                                                              N/A

                       ([@B85])   Diannan small-ear pig (12)      Animal models                                                             N/A (average weight: 15 kg)             N/A                                                                                                                   Chondral defects                       Medial and lateral femoral condyles (MFC and LFC)                        7 mm in diameter and 4 mm in depth

                       ([@B8])    Horse (12)                      A randomized, double-blind,\                                              Median age: 8.5 years old               Mild cartilage changes and normal synovium (arthroscopic examination)                                                 Surgically induced osteoarthritis      The right fetlock joint                                                  Mild cartilage changes (superficial wear line, partial erosion, minor irregularity or thinner cartilage spots)
                                                                  placebo-controlled proof-of-concept study                                                                                                                                                                                                                                                                                                               

                       ([@B9])    Horse (75)                      A randomized, multicenter, double-blinded, and placebo-controlled study   3-23 years old                          Grade 2 or 3 lameness on the AAEP scale; mild-to-moderate response to flexion test; mild-to-moderate joint swelling   Degenerative joint disease             Fetlock joint                                                            Early staged fetlock degenerative joint disease lasting for at least 2 months

                       ([@B16])   Dog (6)                         A prospective placebo-controlled study                                    5-10 years old                          Stable pain and lameness lasting for over 1 month                                                                     OA                                     Humeroradial joint                                                       Mild to severe OA
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

N/A, not available; ICRS, International Cartilage Repair Society; RCT, randomized controlled trial; OA, osteoarthritis; AAEP, American Association of Equine Practitioners.

Preoperative Characteristics of the Patients and Animals {#s3_2}
--------------------------------------------------------

The age of the patients ranged from 7 to 59 years in the 8 human studies ([@B34]; [@B65]; [@B70]; [@B66]; [@B69]; [@B76]; [@B22]; [@B67]). Lesions were mainly located in the tibial plateaus ([@B65]; [@B66]), patella ([@B65]; [@B70]; [@B66]), femoral condyles ([@B65]; [@B70]; [@B66]; [@B69]; [@B76]; [@B67]), femoral trochlea ([@B65]; [@B66]; [@B76]; [@B22]), intercondylar notch ([@B65]), and talus of the ankle joint ([@B34]). The types of lesions included cartilage defects ([@B65]; [@B70]; [@B66]; [@B22]), osteochondral defects ([@B34]; [@B69]), and early- and late-stage osteoarthritis ([@B76]; [@B67]). The International Cartilage Repair Society (ICRS) scores were all grade III--IV ([@B34]; [@B65]; [@B70]; [@B66]; [@B69]; [@B76]; [@B22]; [@B67]).

Types of lesions included spontaneous and induced osteoarthritis ([@B71]; [@B6]; [@B7]; [@B17]; [@B16]; [@B8]; [@B9]), cartilage defects ([@B85]), and osteochondral defects ([@B23]; [@B31]) in the 10 animal studies. The lesions were in the knee joint ([@B6]; [@B23]; [@B17]; [@B31]; [@B85]), fetlock joint ([@B6]; [@B7]; [@B8]; [@B9]), pastern joint ([@B6]), coffin joint ([@B7]), and humeroradial joint ([@B16]). The preoperative characteristics of the patients and animals, such as the age, clinical and imaging examination, types of defects and diseases, location of lesions, and defect size/ICRS grade are shown in [**Table 1**](#T1){ref-type="table"}.

Stem Cell Types and Isolation Methods {#s3_3}
-------------------------------------

Eight human studies ([@B34]; [@B65]; [@B70]; [@B66]; [@B69]; [@B76]; [@B22]; [@B67]) and 1 animal ([@B31]) study used autologous nonculture-expanded condensed PBSCs, 1 animal study ([@B17]) used allogenic condensed PBSCs, 1 animal study ([@B71]) used autologous culture-expanded PB-MSCs, 6 animal studies ([@B6]; [@B7]; [@B23]; [@B85]; [@B8]; [@B9]) used allogenic culture-expanded PB-MSCs, and 1 animal study ([@B16]) used xenogeneic culture-expanded PB-MSCs as seed cells for cartilage repair and regeneration.

All 8 human studies ([@B34]; [@B65]; [@B70]; [@B66]; [@B69]; [@B76]; [@B22]; [@B67]) with 130 patients used a blood cell separator to collect PBSCs. One animal study ([@B17]) with 28 Sprague-Dawley (SD) rats used the density gradient centrifugation (DGC) method to isolate PBSCs. Eight animal studies ([@B71]; [@B6]; [@B7]; [@B31]; [@B85]; [@B16]; [@B8]; [@B9]) with 272 horses, 24 mountain sheep, 12 Diannan small-ear pigs, and 6 dogs used the DGC and plastic adherence (PA) methods to isolate PB-MSCs and PBSCs. Furthermore, one animal study ([@B23]) with 30 New Zealand White rabbits used the erythrocyte lysis and PA methods to isolate PB-MSCs.

Cell density, Dosage, and Implantation Methods {#s3_4}
----------------------------------------------

The seeding dosage in 5 human studies ([@B65]; [@B66]; [@B69]; [@B22]; [@B67]) and 1 animal study ([@B17]) using nonculture-expanded PBSCs as seed cells ranged from 5.0×10^6^ to 3.5×10^7^ cells/ml (or cells/injection), and the seeding dosage in 2 human studies ([@B70]; [@B76]) and 1 animal study ([@B31]) was less than 5.0×10^6^ cells/ml (or cells/injection). In 5 animal studies using PB-MSCs as seed cells, the seeding dosage in 3 studies ranged from 1×10^6^ to 5.0×10^6^ cells/ml (or cells/injection) ([@B71]; [@B23]; [@B16]; [@B8]; [@B9]). One human study ([@B34]) and 3 animal studies([@B6]; [@B7]; [@B85]) did not mention the cell seeding dosage.

Four human studies ([@B34]; [@B70]; [@B69]; [@B22]) and 3 animal studies ([@B23]; [@B31]; [@B85]) implanted cells by surgery, while the remaining 4 human studies ([@B65]; [@B66]; [@B76]; [@B67]) and 7 animal studies ([@B71]; [@B6]; [@B7]; [@B17]; [@B16]; [@B8]; [@B9]) implanted cells by single or repeated intra-articular injections.

Other Therapies and Postoperative Rehabilitation {#s3_5}
------------------------------------------------

All human studies used a variety of other treatments, such as intra-articular debridement ([@B34]; [@B65]; [@B70]; [@B66]; [@B69]; [@B76]; [@B22]; [@B67]), the modified sandwich technique ([@B34]; [@B69]), BMS ([@B65]; [@B70]; [@B66]; [@B67]), high tibial osteotomy (HTO) ([@B65]; [@B67]), and patellofemoral realignment ([@B22]), to promote cartilage repair and regeneration while implanting cells. Strict rehabilitation programmes and passive or active exercises ([@B65]; [@B66]; [@B69]; [@B76]; [@B22]; [@B67]) were followed to avoid early weight bearing, joint stiffness, and adhesion.

The animal studies used other treatments, such as decalcified bone matrix (DBM) scaffolds ([@B22]; [@B85]), collagen-glycosaminoglycan (GAG) scaffolds ([@B31]), platelet-rich plasma (PRP) injections ([@B6]; [@B7]), and equine allogeneic plasma (EAP) ([@B8]; [@B9]), while implanting cells. Except for 2 studies ([@B8]; [@B9]), there were no strict rehabilitation plans in the other animal studies.

[**Table 2**](#T2){ref-type="table"} summarizes the details of the application of PBSCs to cartilage repair and regeneration in humans and animals.

###### 

Treatment Details of PBSCs for Cartilage Repair and Regeneration in Humans and Animals.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                       Study ID   Cell types                                   Cell sources and blood volume (ml)              Isolation methods                   Cellular constituent characterization                                                                                                                                                                       Cell dose                                       Cell stage\                                              Method of delivery                 Surgical procedures                                                                                    Rehabilitation
                                                                                                                                                                                                                                                                                                                                                                                                                               (passage number)                                                                                                                                                                                   
  -------------------- ---------- -------------------------------------------- ----------------------------------------------- ----------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- -------------------------------------------------------- ---------------------------------- ------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------
  **Human studies**    ([@B34])   PBSCs                                        Autologous G-CSF-activated PB                   Blood cell separation               CD34^+^                                                                                                                                                                                                     N/A                                             Fresh condensed stem cells (P0)                          Surgical implantation              Debridement+sandwich technique                                                                         N/A

                       ([@B70])   PBSCs                                        Autologous G-CSF-activated PB, 40-80 ml         Blood cell separation               N/A                                                                                                                                                                                                         8×10^5^ - 3.2×10^6^ cells/ml                    Fresh condensed stem cells (P0)                          Surgical implantation              Debridement + BMS+ PBSC suspension with collagen membrane cover+treatment of co-existing pathologies   N/A

                       ([@B69])   PBSCs                                        Autologous G-CSF-activated PB, 40 ml            Blood cell separation               N/A                                                                                                                                                                                                         1.25×10^6^ - 5.2×10^6^ cells/ml                 Fresh condensed stem cells (P0)                          Surgical implantation              Debridement+modified sandwich technique                                                                Passive and active exercises, non-weight to full-weight bearing

                       ([@B76])   PBSCs                                        Autologous hG-CSF-activated PB                  Leukapheresis                       CD34^+^: 0.34% to 1.04%; CD105^+^: 0.75% to 0.88%;\                                                                                                                                                         TNC: 2.67- 5.99×10^3^ cells/injection           Fresh or cryopreserved condensed stem cells (P0)         Repeated IA injections (3 times)   Debridement +BMS+repeated IA injections (PBSCs+ GFAP +hG-CSF +HA)                                      Non-weight bearing (ambulation with axillary crutch)
                                                                                                                                                                   chondrogenic differentiation                                                                                                                                                                                                                                                                                                                                                                                                                                   

                       ([@B65])   PBSCs                                        Autologous G-CSF-mobilized PB                   Apheresis                           \(i\) Fresh PBSCs: CD34^+^: 1.86%; CD105^+^: 7.24%;\                                                                                                                                                        2.0×10^7^ cells/injection (CD105^+^cells)       Fresh or cryopreserved condensed progenitor cells (P0)   Repeated IA injections (2 times)   Debridement +BMS+HTO(1)+repeated IA injections                                                         CPM+ crutch-assisted partial to full weight bearing
                                                                                                                                                                   (ii) Frozen PBSCs: CD34^+^: 1.22%; CD105^+^: 8.39%                                                                                                                                                                                                                                                                                                                                                                                                             

                       ([@B66])   PBSCs                                        Autologous G-CSF-mobilized PB                   Apheresis                           \(i\) Fresh PBSCs: CD34^+^: 1.86%; CD105^+^: 7.24%;\                                                                                                                                                        2.0×10^7^ cells/injection (CD105^+^cells)       Fresh or cryopreserved condensed stem cells (P0)         Repeated IA injections (8 times)   Debridement +BMS+repeated IA injections                                                                CPM+ crutch-assisted partial to full weight bearing
                                                                                                                                                                   (ii) Frozen PBSCs: CD34^+^: 1.22%; CD105^+^: 8.39%                                                                                                                                                                                                                                                                                                                                                                                                             

                       ([@B67])   PBSCs                                        Autologous G-CSF-mobilized PB                   Apheresis                           \(i\) Fresh PBSCs: CD34^+^: 1.86%; CD105^+^: 7.24%;\                                                                                                                                                        1.0-2.0×10^7^ cells/injection (CD105^+^cells)   Cryopreserved condensed stem cells (P0)                  Repeated IA injections (7 times)   Debridement +BMS+HTO+repeated IA injections                                                            CPM, crutch-assisted partial to full weight bearing
                                                                                                                                                                   (ii) Frozen PBSCs: CD34^+^: 1.22%; CD105^+^: 8.39%                                                                                                                                                                                                                                                                                                                                                                                                             

                       ([@B22])   PBSCs                                        Autologous rhG-CSF-mobilized PB                 Blood cell separation               N/A                                                                                                                                                                                                         3.496×10^7^ cells/ml                            Fresh condensed stem cells (P0)                          Surgical implantation              Debridement+PBSCs with autologous periosteum flap cover+\                                              Strict rehabilitation programme
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           patellofemoral realignment                                                                             

  **Animal studies**   ([@B71])   PB-MSCs                                      Autologous PB, 10 ml                            DGC and PA                          CD29^+^, CD44^+^, CD90^+^, CD79α^-^, MHC II^-^, trilineage differentiation                                                                                                                                  2.5×10^6^ cells/injection                       Culture-expanded cells (P1, P3)                          Repeated IA injections (2 times)   N/A                                                                                                    N/A

                       ([@B6])    PB-MSCs (native or chondrogenic induction)   Allogeneic PB\                                  DGC and PA                          \(i\) Native: CD29^+^, CD44^+^, CD90^+^, CD105^+^; CD45^-^, CD79a^-^, MHC II^-^ and a monocyte/macrophage marker; trilineage differentiation; p63^-^, low in MHC I, Ki67^+^, Col II^+^, and Vimentin^+^.\   N/A                                             Culture-expanded cells (P4)                              Single IA injection                PB-MSCs with or without PRP                                                                            N/A
                                                                               50 ml                                                                               (ii) Chondrogenic induction: aggrecan^+^, Col II^+^, COMP^+^, p63^+^ and GAG^+^; decrease in Ki67.                                                                                                                                                                                                                                                                                                                                                             

                       ([@B7])    PB-MSCs (native or chondrogenic-induced)     Allogeneic PB\                                  DGC and PA                          \(i\) Native: CD29^+^, CD44^+^, CD90^+^, CD105^+^; CD45^-^, CD79a^-^, MHC II^-^ and a monocyte/macrophage marker; trilineage differentiation; p63^-^, low in MHC I, Ki67^+^, Col II^+^, and Vimentin^+^.\   N/A                                             Culture-expanded cells (P4)                              Single IA injection                PB-MSCs with PRP                                                                                       N/A
                                                                               50 ml                                                                               (ii) Chondrogenic induction: aggrecan^+^, Col II^+^, COMP^+^, p63^+^ and GAG^+^; decrease in Ki67.                                                                                                                                                                                                                                                                                                                                                             

                       ([@B23])   PB-MSCs                                      Allogeneic G-CSF-/AMD3100-mobilized PB, 10 ml   Erythrocyte lysis and PA            CD44/CD29^+^, CD45/MHC II^-^, trilineage differentiation                                                                                                                                                    4×10^6^ cells/scaffold                          Culture-expanded cells (P3)                              Surgical implantation              Establishment of animal model + cell-DBM scaffold complex implantation                                 Free movement

                       ([@B31])   PBSCs                                        Autologous PB                                   DGC and PA cultured under hypoxia   Stro-1^+^, CD44^+^, CD90^+^, CD106^+^, CD105^+^, CD146^+^ and CD166^+^; CD34^-^/CD45^-^; trilineage differentiation                                                                                         2.0×10^5^; cells/scaffold                       Fresh concentrated stem cells                            Surgical implantation              Establishment of animal model + cell- collagen-GAG scaffold complex implantation                       Full weight bearing

                       ([@B17])   PBSCs                                        Allogeneic G-CSF-mobilized PB, 200--500 µl      DGC                                 CD34^+^ cells (2.8%), CD34^−^ cells (97.2%)                                                                                                                                                                 5×10^6^ cells/injection                         Cryopreserved condensed stem cells (P0)                  Single IA injection                Establishment of animal model + single IA injection (PBSCs+HA)                                         N/A

                       ([@B85])   PB-MSCs                                      Allogeneic G-CSF-/AMD3100-mobilized PB, 20 ml   DGC and PA                          CD34^-^/CD45^-^;\                                                                                                                                                                                           N/A                                             Culture-expanded cells (P3)                              Surgical implantation              Establishment of animal model + cell-DBM - cytokine scaffold complex implantation                      N/A
                                                                                                                                                                   CD44^+^/CD90^+^                                                                                                                                                                                                                                                                                                                                                                                                                                                

                       ([@B8])    Chondrogenic-induced PB-MSCs                 Allogeneic PB                                   DGC and PA                          Aggrecan^+^, Col II^+^, COMP^+^, p63^+^ and GAG^+^; decrease in Ki67.                                                                                                                                       2×10^6^ cells/injection                         Culture-expanded chondrogenic-induced cells              Single IA injection                PB-MSCs with EAP                                                                                       Rested in a box for 1 week after surgery and exercised on a treadmill for the remainder of the study period

                       ([@B9])    Chondrogenic-induced PB-MSCs                 Allogeneic PB\                                  DGC and PA                          Chondrogenic induction: CD29^+^, CD44^+^, CD90^+^, CD45^-^, MHC II^-^, and a 4.4-fold COMP expression                                                                                                       2×10^6^ cells/injection                         Culture-expanded chondrogenic-induced cells (P10)        Single IA injection                PB-MSCs with EAP                                                                                       A strict rehabilitation protocol
                                                                               50 ml                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

                       ([@B16])   Chondrogenic-induced PB-MSCs                 Xenogeneic PB\                                  DGC and PA                          Chondrogenic induction: CD44^+^, CD90^+^, MHC II^-^, and a 4.4-fold COMP expression                                                                                                                         1×10^6^ cells/injection                         Culture-expanded chondrogenic-induced cells (P10)        Single IA injection                PB-MSCs only                                                                                           Subjected to home confinement and leash walking in the first 10 days after treatment
                                                                               50 ml                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PBSCs, peripheral blood-derived stem cells; G-CSF, granulocyte colony-stimulating factor; PB, peripheral blood; N/A, not available; TNC, total nucleated cells; IA, intra-articular; GFAP, growth factor addition/preservation; hG-CSF, human granulocyte colony stimulating factor; HA, hyaluronic acid; BMS, bone marrow stimulus; HTO, High Tibial Osteotomy; CPM, continuous passive motion; DGC, density gradient centrifugation; PA, plastic adherence; PB-MSCs, peripheral blood mesenchymal stem/stromal cells; PRP, Platelet-rich plasma; MHC, major histocompatibility complex; Col, collagen; COMP, cartilage oligomeric matrix protein; GAG, glycosaminoglycan; DBM, decalcified bone matrix; ciMSCs, chondrogenic induced mesenchymal stem cells; EAP, equine allogeneic plasma.

Efficacy and Safety of Treatment {#s3_6}
--------------------------------

We assessed the adverse events and the clinical, radiographic, and histologic results to determine the treatment efficacy and safety ([**Table 3**](#T3){ref-type="table"}).

###### 

Efficacy and safety of treatment.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                       Study ID   Follow-up period      Clinical outcomes                                                     Radiology                                                                                         Second-look arthroscopy/\                                                                                               Histological assessment                                                                                                                     Adverse effects
                                                                                                                                                                                                                                gross morphology evaluation                                                                                                                                                                                                                                         
  -------------------- ---------- --------------------- --------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------
  **Human studies**    ([@B34])   6 months to 3 years   Improved Magee score                                                  MRI: regenerative tissue with same signals as normal cartilage                                    N/A                                                                                                                     N/A                                                                                                                                         Longer bone healing\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    (1 patient)

                       ([@B70])   6 years               \(i\) Improved KOOS and Lysholm scales, relief of VAS scale;\         MRI: defects were refilled with regenerative tissue                                               N/A                                                                                                                     N/A                                                                                                                                         \(i\) Intra-articular adhesions (1 patient);\
                                                        (ii) Approximately 90% of patients with good results                                                                                                                                                                                                                                                                                                                                                                                        (ii) Joint pain with intermittent exudates and movement limitations (1 patient)

                       ([@B69])   5 years               \(i\) Improved KOOS and Lysholm scales, relief of VAS scale;\         MRI: satisfactory reconstruction of the cartilaginous surface and good regenerative integration   N/A                                                                                                                     N/A                                                                                                                                         None
                                                        (ii) 92% of patients with good results                                                                                                                                                                                                                                                                                                                                                                                                      

                       ([@B76])   6 months              Improved WOMAC and KOOS scales                                        N/A                                                                                               N/A                                                                                                                     Succeeded in regenerating articular cartilage                                                                                               Mild swelling and discomfort

                       ([@B65])   10-26 months          N/A                                                                   X-ray: reappearance of medial articulation (1)                                                    Regenerated articular cartilage with a smooth surface and excellent integration with the surrounding native cartilage   Regenerated full-thickness articular hyaline cartilage                                                                                      Minimal discomfort from PBSCs harvesting and IA injection

                       ([@B66])   18 months             No IKDC score difference compared to the control group                Improved MRI morphologic scores                                                                   Regenerated articular cartilage with a smooth surface and excellent integration with the surrounding native cartilage   Improved total ICRS II histologic scores                                                                                                    Deep vein thrombosis (1 patient in the control group)

                       ([@B67])   15-58 months          Restoration of lower limb alignment                                   X-ray: reappearance of the medial compartment                                                     Smooth regenerated articular cartilage and excellent integration with the surrounding native cartilage                  \(i\) Improved ICRS II scores;\                                                                                                             None
                                                                                                                                                                                                                                                                                                                                                        (ii) High-quality cartilage regeneration resembling hyaline cartilage                                                                       

                       ([@B23])   7.5 years             Improved IKDC 2000 subjective score, Lysholm score and Tegner score   \(i\) CT: subchondral bone recovery;\                                                             Regenerated articular cartilage with a smooth surface, but with a slightly yellowish and shallow morphology             N/A                                                                                                                                         None
                                                                                                                              (ii) MRI: near normal cartilage-like tissue regeneration                                                                                                                                                                                                                                                                                                              

  **Animal studies**   ([@B71])   4 months              Improved visual gait and objective pressure plate analysis            X-ray and B-ultrasound: no considerable changes                                                   N/A                                                                                                                     N/A                                                                                                                                         None

                       ([@B6])    12 months             \(i\) Improved short- and long-term clinical evolution scores;\       N/A                                                                                               N/A                                                                                                                     N/A                                                                                                                                         None
                                                        (ii) Relief from clinical lameness, flexion pain and joint effusion                                                                                                                                                                                                                                                                                                                                                                         

                       ([@B7])    18 weeks              \(i\) Improved short- and long-term clinical evolution scores;\       N/A                                                                                               N/A                                                                                                                     N/A                                                                                                                                         Moderate flare reaction (without long-term effects, 3 horses)
                                                        (ii) Relief from clinical lameness and locomotor disorder                                                                                                                                                                                                                                                                                                                                                                                   

                       ([@B23])   24 weeks              N/A                                                                   N/A                                                                                               Cartilage regeneration comparable to BM-MSCs                                                                            Improved histological grading scale                                                                                                         N/A

                       ([@B31])   26 weeks              N/A                                                                   N/A                                                                                               Improved ICRS macroscopic scores                                                                                        Improved modified O\'Driscoll score                                                                                                         None

                       ([@B17])   6 weeks               N/A                                                                   N/A                                                                                               N/A                                                                                                                     Decreased cellular necrosis, apoptosis, loss of chondrogenic proteins, and modified Mankin scores                                           N/A

                       ([@B85])   12 weeks              N/A                                                                   N/A                                                                                               Cartilage regeneration similar to normal cartilage tissue                                                               Improved O\'Driscoll score                                                                                                                  N/A

                       ([@B8])    11 weeks              Improvements in visual and objective lameness;                        No significant radiographic changes                                                               Significantly less wear lines and synovial hyperaemia                                                                   \(i\) A significantly higher GAG concentration in the synovial fluid;\                                                                      None
                                                                                                                                                                                                                                                                                                                                                        (ii) Significantly enhanced Alcian Blue uptake and area % of COMP and Collagen II in the cartilage adjacent to the osteochondral fragment   

                       ([@B9])    3 weeks-1 year        \(i\) Improved short- and long-term clinical evolution scores;\       N/A                                                                                               N/A                                                                                                                     N/A                                                                                                                                         Nasal discharge (2 horse in the IVP group and 1 in the CP group)
                                                        (ii) Relief from clinical lameness, flexion pain and joint effusion                                                                                                                                                                                                                                                                                                                                                                         

                       ([@B16])   12 weeks              Relief from pain and lameness                                         No significant radiographic changes                                                               N/A                                                                                                                     N/A                                                                                                                                         One of the six dogs had vomiting and/or diarrhea twice (one after placebo treatment and one after MSCs treatment)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The follow-up time of the 8 human trials ranged from 6 months to 7.5 years. The clinical evaluation results of 5 studies showed that Magee score ([@B34]), KOOS scales ([@B70]; [@B69]; [@B76]), Lysholm scales ([@B70]; [@B69]), WOMAC scales ([@B76]), IKDC 2000 subjective score ([@B22]) or Tegner score ([@B22]) were improved, VAS scales ([@B70]; [@B69]) were relieved, and Skowroski et al. ([@B70]; [@B69]) reported 90 and 92% of patients with good results in 2012 and 2013, respectively. One study ([@B66]) reported that there was no IKDC score difference compared to the control group. One study ([@B67]) reported lower limb line recovery, and one study ([@B65]) did not report clinical evaluation results.

Five animal studies ([@B71]; [@B6]; [@B7]; [@B8]; [@B9]) on horses reported improved visual gait, objective pressure plate analysis, short- and long-term clinical evolution scores, and relief of visual and objective lameness, flexion pain, and joint effusion.

Radiological examination, which is a non-invasive examination method, was widely used to evaluate the efficacy of cartilage repair and regeneration. Seven human studies used MRI ([@B34]; [@B70]; [@B66]; [@B69]; [@B22]), X-ray ([@B65]; [@B67]) or CT ([@B22]) to evaluate the repair effect and reported improved MRI morphologic scores, regenerative tissue with the same signal as normal cartilage, subchondral bone recovery, or reappearance of the medial compartment. However, radiological examination was rarely used in the animal studies. Three animal studies ([@B71]; [@B16]; [@B8]) reported no significant radiographic changes.

Four human studies ([@B65]; [@B66]; [@B22]; [@B67]) evaluated cartilage repair with the method of second-look arthroscopy and suggested that cartilage regeneration was comparable to BM-MSCs with improved ICRS macroscopic scores, cartilage regeneration similar to normal cartilage tissue, or significantly fewer wear lines and synovial hyperaemia.

Histopathological examination is the gold standard for evaluation. Four human studies ([@B65]; [@B66]; [@B76]; [@B67]) reported high-quality cartilage regeneration resembling hyaline cartilage and/or improved total ICRS II histologic scores. Five animal studies ([@B23]; [@B17]; [@B31]; [@B85]; [@B8]) reported an improved histological grading scale, modified O\'Driscoll score, modified Mankin scores, O\'Driscoll score, or significantly higher Alcian blue uptake.

In eight human studies, the major adverse events included longer bone healing (1 patient) ([@B34]), intra-articular adhesions (1 patient) ([@B70]), joint pain with intermittent exudates and motion limitation (1 patient) ([@B70]), mild swelling ([@B76]), and minimal discomfort during PBSCs harvesting and intra-articular (IA) injection ([@B65]). No serious adverse events occurred during the isolation and treatment of PBSCs. In one human study ([@B66]), a case of deep vein thrombosis occurred in the control group. In animal studies, moderate flare reactions (3 in 165 horses) ([@B6]), nasal discharge (3 in 75 horses) ([@B9]), and vomiting and diarrhea (1 in 6 dogs) ([@B16]) occurred without long-term effects.

Discussion {#s4}
==========

Researchers have conducted investigations of PBSCs in cartilage repair and regeneration because of the advantages of PBSCs and limitations of chondrogenic progenitor cells from other sources, such as bone marrow ([@B2]), synovial membranes ([@B54]), and adipose tissue ([@B42]). Increasing evidence has shown that PB-MSCs have a similar potential for proliferation and trilineage differentiation as BM-MSCs and might be a promising source of seed cells for cartilage repair ([@B79]) since Fernández et al. ([@B19]) reported the presence of stromal cells in hG-CSF-mobilized PB from patients with breast cancer for the first time in 1997. However, PBSCs were not used to treat chondral defects and promote cartilage regeneration *in vivo* until 2004, as reported by investigators in Poland ([@B34]).

For the first time, this review comprehensively evaluated the feasibility, efficacy, and safety of using PBSCs for cartilage repair and regeneration *in vivo* by analyzing the preoperative characteristics, therapeutic details, outcomes, and adverse events reported in currently published literature. This review might provide new insights and strategies for further foundational research and clinical applications of PBSCs.

Autologous nonculture-expanded PBSCs are easy to harvest and manipulate from G-CSF-activated PB without the concerns of disease transmission, immune rejection, and ethical issues ([@B22]; [@B67]). PBSCs are currently the most commonly used cell type for cartilage repair in all stem cell types derived from PB. It has been demonstrated that nonculture-expanded PBSCs comprise haematopoietic stem cells (HSCs), fibrocytes, a population of MSCs/mesenchymal progenitor cells (MSCs/MPCs), white blood cells, platelets, growth factors, and a small percentage of red blood cells ([@B73]; [@B10]). When PBSCs are being cultured, other impure cell types except MSCs/MPCs are not present anymore. To a certain degree, the cell composition of nonculture-expanded PBSCs is similar to that of the bone marrow-derived buffy coat (BMBC), which is separated from bone marrow using a Ficoll gradient centrifugation system. The bone marrow-derived buffy coat has been widely used as a source of MSCs for cartilage repair and regeneration and has achieved good to excellent results ([@B20]; [@B35]). Several possible mechanisms of action of PBSCs might contribute to cartilage repair. Hopper et al. ([@B30]; [@B32]) found that PBSCs stimulate the upregulation of eight genes associated with chondrogenic differentiation of knee infrapatellar fat pad-derived MSCs, increase the total number of MSCs, increase native chondrocyte migration, and accelerate the rate of cell movement. Exogenous MSCs, HSCs, and growth factors in PBSCs initiate cartilage regeneration and augment endogenous MSC recruitment from bone marrow to subchondral drilling sites ([@B40]; [@B56]; [@B67]). [@B17] suggested that PBSCs prevent the progression of papain-induced knee OA in a rat model by reducing articular surface fibrillation, irregularity, and erosion, and by inhibiting chondrocyte necrosis and loss of chondrogenic proteins. HSCs and non-HSCs, such as MSCs, endothelial progenitor cells, and very small embryonic-like (VSEL) cells, contained in PBSCs might play an important role through a paracrine mechanism ([@B41]; [@B56]). Although the term "PBSCs" had different expressions in different studies, such as PB progenitor cells (PBPCs) ([@B65]) and PB mononuclear cells (PBMCs) ([@B31]), we found that the cell acquisition method and cell composition were basically the same. For the convenience of expression, "PBSCs" was used uniformly in this paper.

The transplantation of autologous culture-expanded PB-MSCs requires two procedures for obtaining patient cells and transplanting the cells after cultivation, which prolongs hospital stays, increases costs and risks contamination related to *in vitro* culture, possibly limiting the clinical application of autologous PB-MSCs ([@B66]; [@B23]). Moreover, an age-related decline in MSC numbers, proliferation, and clonogenicity, which lead to more difficult culture *in vitro* and a longer culture cycle than MSCs from other tissue sources, might be another significant cause for the lack of clinical applications of autologous culture-expanded PB-MSCs ([@B39]; [@B5]; [@B14]; [@B72]; [@B79]). For example, MSCs derived from bone marrow, synovium or adipose tissue reached 80--90% confluence within 7 to 14 days ([@B83]; [@B36]; [@B68]). However, MSCs derived from PB did not achieve the same confluence until about 21 days after primary culture ([@B13]). It takes longer to obtain the culture-expanded PB-MSCs than other tissue-derived MSCs. The presence of MSCs in human PB is debatable and their identification may be hampered, among others, by: (i) their low frequency in PB of healthy individuals, and (ii) the large biological variations related to donor age, pathology, disease status, and corresponding treatment regimens ([@B21]; [@B51]). Most investigators agree that their frequency in blood is low in healthy individuals, but that the amounts of circulating MSCs may increase under special mobilization conditions, thus supporting the notion that MSCs can be transiently found circulating in blood ([@B52]). Jain et al. provide evidence that MSCs can be found in PB and apheresis product of patients treated with a typical G-CSF-based HSCs mobilization regimen by using flow cytometry ([@B33]). However, a systematic review strongly indicated the existence of MSCs in the PB of animals ([@B79]), this might be because researchers could improve the success rate of PB-MSCs in animal studies by optimizing mobilization and culture procedures, prolonging the culture time, and increasing the number of animals and the frequency of blood drawn ([@B59]; [@B75]; [@B72]). To et al. noted in a baboon model that MSC mobilization and colony-forming unit fibroblast (CFUF) in PB in response to G-CSF did only occur when adding stem cell factor ([@B75]). Pitchford et al. found, that MSCs/CFU-F were not found in mice PB post-mobilization with G-CSF, but when adding vascular endothelial growth factor and CXCR4-antagonist ([@B59]). Spaas et al. systematically studied the isolation and culture methods, cell characteristics, and clinical safety of equine PB-MSCs, and applied them to many veterinary clinical studies, such as promoting cartilage repair, cutaneous wound healing, and healing of tendon and ligament lesions ([@B72]; [@B4]; [@B50]; [@B8]). Allogenic or xenogeneic MSCs banks, improving the mobilization and purification techniques, and shortening the culture cycle might effectively account for deficiencies in autologous MSCs, reduce the burden on both patients and treatment providers, and promote the development of single-stage procedures ([@B53]; [@B58]).

MSCs inhibit immune responses and are not restricted by the HLA system through immune evasion and immune privilege mechanisms ([@B57]; [@B77]). Moreover, the strong immunomodulatory and immunosuppressive properties of MSCs may play an important role in modifying graft-versus-host reactions during allogenic transplantations ([@B43]). Two animal studies used allogenic native and chondrogenic-induced PB-MSCs as a treatment for degenerative joint disease in horses and significantly improved the short- and long-term effects without serious adverse events ([@B6]; [@B7]). [@B77] performed an RCT to assess the feasibility and safety of treating osteoarthritis with allogeneic MSCs in humans, and they concluded that allogeneic MSCs might be a convenient and effective alternative to autologous MSCs for the treatment of OA in the knee without serious transplantation-related adverse events. A number of published papers have indicated that transplanted MSCs influence the local microenvironment of cartilage by paracrine actions, such as the secretion of various growth factors, cytokines, and chemokines, to exert anti-inflammatory, anti-apoptotic, and anti-fibrotic effects on chondrocytes([@B42]; [@B48]). Another possible mechanism of action of MSCs in cartilage repair and regeneration is that transplanted progenitor cells migrate to damaged cartilage areas and differentiate into chondrocytes and osteocytes ([@B10]). The fate of MSCs injected into the articular cavity can be monitored by labelling with green fluorescent protein (GFP) or carboxyfluorescein diacetate succinimidyl ester (CFDA-SE) ([@B26]; [@B63]). Murphy et al. found that the implantation of MSCs into the knee joints of goats with OA showed a strong and sustained effect in promoting cartilage repair. However, further tracing the labelled MSCs showed that the cell retention rate was very low, usually about 3%, and most cells disappeared within a few days ([@B55]). This suggests that MSCs may not directly differentiate into chondrocytes to participate in tissue repair *in vivo*, but promote cartilage regeneration through other mechanisms. In recent years, more and more researchers believed that exosomes secreted by MSCs played an important role in cartilage repair and regeneration ([@B49]; [@B82]; [@B37]; [@B46]). Exosomes are generally considered as communication vectors between cells, and carry a large number of complex nucleic acids (mRNA and miRNA lncRNA), proteins and lipids that can regulate and restore extracellular matrix (ECM) homeostasis ([@B15]). For example, MSCs exosomes with overexpressing of miR-140-5p blocked other Wnt signals *in vitro* by inhibiting v-ral simian leukemia viral oncogene homolog A (RalA) and activating sex determining region Y-box 9 (SOX9), and regulate the expression of Col II and aggrecan (ACAN) *in vivo* to promote cartilage regeneration ([@B74]). It may also be an important mechanism for PBSCs to promote cartilage repair.

Blood cell separation is the most commonly used method for collecting PBSCs. It is a developed and simple technique that has been widely used in the treatment of systemic blood diseases. In a monocyte suspension isolated by blood cell separation, CD105^+^ cells have been shown to be more abundance than CD34^+^ cells, and the proportion of CD105^+^ cells increased after cryopreservation ([@B65]). However, there is no study on the subsequent isolation and culture of PB-MSCs from PBSCs collected by blood cell separation. The current standard methods of PB-MSC isolation are DGC (such as Ficoll, Lymphoprep, and Percoll) and PA ([@B5]).

As one of the most fundamental parameters that might influence the outcome of cartilage repair ([@B27]), the optimal density or dosage of PBSCs used for cartilage regeneration in different methods and species has not been fully investigated. Skowroński et al. ([@B69]) reported a slightly poorer outcome of cartilage repair in a group treated with a bone marrow concentrate than a group treated with fresh condensed PBSCs, and they attributed this result to the lower cell count in the suspension obtained from bone marrow. The main concern of using nonculture-expanded PBSCs to promote tissue regeneration is the low content of MSCs within harvests. The number of HSCs (with a CD34^+^ surface marker) and MSCs (with a CD105^+^ surface marker) were quantified by flow cytometry in a study carried out by Saw et al. ([@B65]). The flow cytometry result showed that the proportion of CD105^+^ cells in fresh PBSC suspension was 7.24% (2.32×10^6^ cells/ml). Interestingly, the proportion of CD105^+^ cells reached 8.39% (2.69×10^6^ cells/ml) after cryopreservation. However, the CD105^+^ cell counts vary between different studies. Turajane et al. ([@B76]) reported that a proportion of CD105^+^ cells ranging from 0.75 to 0.88%. The difference of the proportion of CD105^+^ cells in the two studies was probably due to the younger patients in the previous study and the older patients in the latter.

To increase the yield of MSCs from autologous PB, repeated intra-articular injections were implemented in some studies ([@B65]; [@B66]; [@B76]; [@B67]), and they speculated that this method is more efficacious than a single injection for the enhancement of cartilage repair on the basis of a suggestion from an animal study ([@B64]). However, repeated IA injections of culture-expanded allogeneic MSCs is not recommended due to a significant adverse response that might be initiated by immune recognition of allogeneic MSCs after a second exposure ([@B38]).

Currently, the optimal seeding density of MSCs also remains unknown. A systematic review showed that the dose of MSCs for cartilage repair varies from 2×10^6^--7.7×10^7^ cells in human clinical studies ([@B24]). Gupta et al. ([@B27]) found that an MSC dose of 2.5×10^7^ with the IA injection method for treating OA showed the best improvement for relieving pain and the lowest adverse events compared with other higher dose groups. They hypothesized that a higher cell dosage causes cell aggregation and subsequent cell death due to limited space in the knee joint. A prospective RCT demonstrated that an intra-articular injection of cultured MSCs with a mean dose of 1.46×10^7^ cells for treating OA is effective in improving clinical and magnetic resonance observation of cartilage repair tissue (MOCART) scores after a 2-year follow-up ([@B81]). Given the limited evidence of clinical application of PB-MSCs in cartilage repair and regeneration, the optimal therapeutic dose of PB-MSCs remains to be further studied.

Moreover, a number of studies have reported concomitant procedures, such as abrasion arthroplasty ([@B3]), autologous bone grafting to restore bone mass ([@B62]), treatment of co-existing pathologies ([@B81]), and BMS ([@B35]), PRP ([@B8]) and HA ([@B11]) to repair cartilage defects. Thus, the abovementioned methods are recommended to supplement PBSCs for cartilage repair and regeneration. A rigorous postoperative rehabilitation programme is required to protect grafts and avoid the effusion of PBSC suspensions ([@B69]; [@B22]).

Compared with other tissue-derived MSCs, the culture of PB-MSCs was relatively difficult, which resulted in less reports of its application *in vivo*, but it does not affect its application prospects. On the contrary, it is ethically more suitable for clinical application due to its unique advantages, such as minimally invasive sample acquisition procedure, repeatable sampling, and high recognition of patients ([@B22]; [@B23]; [@B78]; [@B13]). In this review, we have summarized all the currently published researches on the use of PBSCs for cartilage repair and regeneration *in vivo*. Although only 5 human and veterinary clinical studies ([@B66]; [@B69]; [@B16]; [@B8]; [@B9]) had a control group, the results were still very useful for readers, and can reflect the progress and problems in this field to a certain extent.

Conclusion {#s5}
==========

This review evaluated the use of PBSCs in cartilage repair and regeneration *in vivo* for the first time. Autologous PBSCs are easy to obtain and are free of transmittable diseases, infection risks, and medical ethical restrictions. They are currently the most commonly used cell type for cartilage repair among all stem cell types derived from PB. Blood cell separation technology is developed, simple, and convenient, making it the most commonly used method to obtain PBSC suspensions. Allogeneic culture-expanded PB-MSCs are more widely used in animal research and are potential seed cell types for cartilage repair and regeneration in the future. DGC and PA are the most commonly used methods for PB-MSC isolation. Improving the purification technology and shortening the culture cycle of culture-expanded PB-MSCs will obviously promote the researchers\' interest. PBSCs are safe in cartilage repair and regeneration. Although all reviewed articles indicated that using PB as a cell source enhances cartilage repair and regeneration *in vivo* by the IA injection and surgery implantation methods, we should maintain a prudent attitude towards the positive therapeutic effect of PBSCs considering the deficiency of studies with a high level of evidence, incomplete assessment system of outcomes, and combined use of multiple other treatments. In summary, the use of PBSCs in cartilage repair and regeneration warrants considerable efforts for further investigations due to its superiorities and safety in clinical settings and positive effects despite limited evidence in human.
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